Buchumschlag

Machine Learning for Prediction of Drug Concentrations: Application and Challenges

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Shuqi Huang, Qihan Xu, Guoping Yang, Junjie Ding, Qi Pei
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Clinical Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Machine Learning Prediction of Unbound Ceftriaxone Concentrations in Children: Capturing Developmental Changes in Protein Binding for Precision Dosing
von: Bo‐Hao Tang, et al.
Veröffentlicht: (2026)

Chat GPT and the Challenges to Detect Potential Drug–Drug Interactions Related to QT Prolongation
von: Emanuel Raschi, et al.
Veröffentlicht: (2025)

Assessment of Efficacy Evidence for Approvals of Novel Drugs in China Between 2018 and 2022
von: Yang Xu, et al.
Veröffentlicht: (2024)

Insights into Clinical Trials for Drugs Targeting MASLD: Progress, Challenges, and Future Directions
von: Yu Wu, et al.
Veröffentlicht: (2025)

Beyond Population‐Level Targets for Drug Concentrations: Precision Dosing Needs Individual‐Level Targets that Include Superior Biomarkers of Drug Responses
von: Thomas M. Polasek, et al.
Veröffentlicht: (2024)

Using Machine Learning to Individualize Treatment Effect Estimation: Challenges and Opportunities
von: Alicia Curth, et al.
Veröffentlicht: (2024)

A Comprehensive CYP2D6 Drug–Drug–Gene Interaction Network for Application in Precision Dosing and Drug Development
von: Simeon Rüdesheim, et al.
Veröffentlicht: (2025)

Strategy for Identifying Rational Sensitivity Analysis Using PBPK Modeling for Precipitant Drug–Drug Interaction Predictions
von: Kunal S. Taskar, et al.
Veröffentlicht: (2025)

Challenges and Possible Strategies to Address Them in Rare Disease Drug Development: A Statistical Perspective
von: Jie Chen, et al.
Veröffentlicht: (2025)

Application of Physiologically Based Pharmacokinetic Modeling to Inform Dose Selection of Mezigdomide in a Phase I Drug–Drug Interaction Study
von: Joseph Burnett, et al.
Veröffentlicht: (2025)

Analysis of Real‐World Data Utilization in the Orphan Drug Approval Process: Focusing on New Drug Marketing Applications Submitted to the FDA
von: Minji Kim, et al.
Veröffentlicht: (2026)

Insights into PK ‐Based Bridging for Products Using a Common Autoinjector Platform: A Review of 16 Autoinjectors in 14 Biological License Applications
von: Zhe Li, et al.
Veröffentlicht: (2026)

Biomarker‐Based Prediction of OATP1B1 Activity in Clinical Routine—Investigating Coproporphyrins as Markers for Drug–Drug–Gene Interactions
von: Leila Potzel, et al.
Veröffentlicht: (2026)

Machine Learning‐Based Prediction of Escitalopram and Sertraline Side Effects With Pharmacokinetic Data in Children and Adolescents
von: Ethan A. Poweleit, et al.
Veröffentlicht: (2024)

Artificial Intelligence/Machine Learning: The New Frontier of Clinical Pharmacology and Precision Medicine
von: Qi Liu, et al.
Veröffentlicht: (2024)

Prediction of the Intra‐T Lymphocyte Tacrolimus Concentration after Kidney Transplantation with Population Pharmacokinetic Modeling
von: Suwasin Udomkarnjananun, et al.
Veröffentlicht: (2024)

Phenotypic Models of Drug–Drug‐Gene Interactions Mediated by Cytochrome Drug‐Metabolizing Enzymes
von: Roberto Viviani, et al.
Veröffentlicht: (2024)

Repurposing Drugs for Malaria through a Human Dose Prediction: A Case Study with Berzosertib
von: Devasha Redhi, et al.
Veröffentlicht: (2026)

Machine Learning and Artificial Intelligence in PK‐PD Modeling: Fad, Friend, or Foe?
von: Zhonghui Huang, et al.
Veröffentlicht: (2024)

Combination Therapy With Guselkumab and Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Pharmacokinetics, Immunogenicity and Drug–Drug Interactions
von: Jie Shao, et al.
Veröffentlicht: (2024)

Using Machine Learning to Determine a Suitable Patient Population for Anakinra for the Treatment of COVID‐19 Under the Emergency Use Authorization
von: Qi Liu, et al.
Veröffentlicht: (2024)

Real‐World Evidence in New Drug and Biologics License Application Approvals During Fiscal Years 2020–2022
von: Gabriel K. Innes, et al.
Veröffentlicht: (2025)

Physiologically Based Pharmacokinetic Modeling to Investigate the Disease‐Drug–Drug Interactions between Voriconazole and Nirmatrelvir/Ritonavir in COVID‐19 Patients with CYP2C19 Phenotypes
von: Peile Wang, et al.
Veröffentlicht: (2024)

Methodology for Good Machine Learning with Multi‐Omics Data
von: Thibaud Coroller, et al.
Veröffentlicht: (2024)

Drug–Drug Interaction Between Dihydroartemisinin–Piperaquine and Sulfadoxine‐Pyrimethamine During Malaria Chemoprevention in Pregnant Women
von: Norah Mwebaza, et al.
Veröffentlicht: (2024)

Therapeutic Drug Monitoring of Oral Oncology Drugs: Finding the Right Nails
von: Niels A. D. Guchelaar, et al.
Veröffentlicht: (2024)

Prediction of Acute Liver Injury Trajectory in Patients Following Acetaminophen Overdose: A Multibiomarker Machine Learning Proof‐of‐Concept Study
von: Chris Humphries, et al.
Veröffentlicht: (2026)

Drug Interactions Brewing
von: Matthijs W. van Hoogdalem, et al.
Veröffentlicht: (2025)

Gut Microbiota in Patients with Tuberculosis Associated with Different Drug Exposures of Antituberculosis Drugs
von: Yue Zhu, et al.
Veröffentlicht: (2025)

Clinical Evaluation of Drug–Drug Interactions with Obeldesivir, an Orally Administered Antiviral Agent
von: Chi‐Chi Peng, et al.
Veröffentlicht: (2025)

New Horizons of Model Informed Drug Development in Rare Diseases Drug Development
von: Amitava Mitra, et al.
Veröffentlicht: (2024)

Therapeutic Drug Monitoring of Oral Oncology Drugs: Another Example of Maslow's Hammer
von: Mark J. Ratain
Veröffentlicht: (2024)

Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug Interactions
von: Cornelius Cilliers, et al.
Veröffentlicht: (2024)

Thinking Three‐Dimensionally: A Self‐ and Externally‐Controlled Approach to Screening for Drug–Drug–Drug Interactions Among High‐Risk Populations
von: Emily K. Acton, et al.
Veröffentlicht: (2024)

Predictive Modeling of Drug‐Related Adverse Events with Real‐World Data: A Case Study of Linezolid Hematologic Outcomes
von: Anu Patel, et al.
Veröffentlicht: (2024)

Dose Determinations at Drug Approval Reviews: FDA‐Approved Drugs in Past 5 Years
von: Sachiko Mita, et al.
Veröffentlicht: (2025)

Prediction of Local Drug Exposure of Dry Powder Inhaler CXG87 (budesonide/formoterol) Using Physiologically‐Based Pharmacokinetic Model
von: Yuran Cao, et al.
Veröffentlicht: (2025)

Advances in Clinical Therapies for Huntington's Disease and the Promise of Multi‐Targeted/Functional Drugs Based on Clinicaltrials.gov
von: Chunhui Huang, et al.
Veröffentlicht: (2024)

Association Discovery Approach in Healthcare Big Data to Identify Drug Safety and Drug Repurposing Signals
von: George S. Q. Tan, et al.
Veröffentlicht: (2025)

Impact of Model‐Informed Drug Development on Drug Development Cycle Times and Clinical Trial Cost
von: Vaishali Sahasrabudhe, et al.
Veröffentlicht: (2025)